Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Neogen's ebitda for the twelve months ending Aug 31, 2026 was $108.92M. For fiscal 2026 it was $94.70M. Over ten years it grew 3.3% a year on average. The highest annual figure on record is $175.30M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $94.70M | – |
| FY2025 | May 31, 2025 | -$941.50M | -637.1% |
| FY2024 | May 31, 2024 | $175.30M | +39.2% |
| FY2023 | May 31, 2023 | $125.89M | +52.9% |
| FY2022 | May 31, 2022 | $82.31M | -13.5% |
| FY2021 | May 31, 2021 | $95.21M | +10.8% |
| FY2020 | May 31, 2020 | $85.92M | +0.2% |
| FY2019 | May 31, 2019 | $85.72M | -1.8% |
| FY2018 | May 31, 2018 | $87.25M | +9.6% |
| FY2017 | May 31, 2017 | $79.64M | +16.1% |
| FY2016 | May 31, 2016 | $68.57M | +7.5% |
| FY2015 | May 31, 2015 | $63.77M | +21.3% |
| FY2014 | May 31, 2014 | $52.57M | +9.3% |
| FY2013 | May 31, 2013 | $48.12M | +20.6% |
| FY2012 | May 31, 2012 | $39.91M | -3.0% |
| FY2011 | May 31, 2011 | $41.16M | +31.5% |
| FY2010 | May 31, 2010 | $31.31M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $27.30M | +110.0% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $32.50M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $25.62M | -26.3% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $23.51M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $13.00M | -59.4% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$580.90M | -1488.9% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $34.75M | -16.6% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$427.44M | -1072.9% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $32.06M | -33.0% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $41.82M | -19.4% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $41.67M | -3.4% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $43.93M | +130.2% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $47.87M | +306.0% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $51.86M | +117.1% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $43.16M | +239.8% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $19.08M | +4.3% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $11.79M | -57.0% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $23.89M | -8.8% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $12.70M | -40.5% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $18.30M | -23.9% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $27.43M | +16.1% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $26.19M | +5.6% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $21.36M | +21.4% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $24.05M | +5.4% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $23.62M | +14.1% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $24.80M | +6.3% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $17.60M | -7.7% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $22.82M | +1.1% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $20.70M | -0.2% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $23.33M | -3.8% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $19.07M | -6.2% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $22.57M | +1.3% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $20.75M | +1.6% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $24.24M | +5.4% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $20.33M | +12.9% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $22.27M | +9.1% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $20.42M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $23.00M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $18.00M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $20.41M | – |
See a number that looks wrong?